High-Resolution Melting Assay for Genotyping Variants of the CYP2C19 Enzyme and Predicting Voriconazole Effectiveness-Reference-Cited by-同舟云学术

High-Resolution Melting Assay for Genotyping Variants of the CYP2C19 Enzyme and Predicting Voriconazole Effectiveness

Published:2019-06 Issue:6 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Bernal-Martínez L.¹²,Alcazar Fuoli L.¹²,Miguel-Revilla B.¹,Carvalho A.³⁴,Cuétara Garcia M. S.⁵,Garcia-Rodriguez J.⁶,Cunha C.³⁴,Gómez-García de la Pedrosa E.⁷,Gomez-Lopez A.¹²

Affiliation:

1. Mycology Reference and Research Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain

2. Spanish Network for Research in Infectious Diseases (REIPI), Instituto de Salud Carlos III, Madrid, Spain

3. Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal

4. ICVS/3B’s–PT Government Associate Laboratory, Braga/Guimarães, Portugal

5. Microbiology Laboratory, Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain

6. Department of Microbiology and Parasitology, Hospital Universitario La Paz-H Carlos III, IdiPAZ, Madrid, Spain

7. Department of Microbiology, Hospital Universitario Ramon y Cajal, Instituto de Investigación Ramón y Cajal (IRYCIS), Madrid, Spain

Abstract

Voriconazole is a triazole antifungal agent recommended as primary treatment for invasive aspergillosis, as well as some other mold infections. However, it presents some pharmacokinetic singularities that lead to a great variability intra- and interindividually, nonlinear pharmacokinetics, and a narrow therapeutic range.

Funder

MEC | Instituto de Salud Carlos III

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02399-18

Reference40 articles.

1. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients

2. Diagnostics and susceptibility testing in Aspergillus

3. Recomendaciones sobre el tratamiento de la enfermedad fúngica invasiva por Aspergillus spp. y otros hongos filamentosos de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2011

4. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

5. Voriconazole

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors Influencing Blood Concentration of Voriconazole and Therapeutic Drug Monitoring in Patients with Child–Pugh Class C Cirrhosis;Journal of Clinical Pharmacy and Therapeutics;2023-02-14

2. Blocker displacement amplification mediated PCR based screen-printed carbon electrode biosensor and lateral flow strip strategy for CYP2C19*2 genotyping;Biosensors and Bioelectronics;2022-07

3. Antifungal Drugs TDM: Trends and Update;Therapeutic Drug Monitoring;2022-02

4. Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies;Xenobiotica;2021-08-24